Chlamydia trachomatis and Mycoplasma genitalium Plasma Antibodies in Relation to Epithelial Ovarian Tumors

Table 3

Prevalence of plasma antibodies in women with malignancies classified as type II tumors (𝑛=44) compared with matched controls and women with benign conditions.

Tumor group and antibodies analyzed	Antibody-positive 𝑛 (%)		Cases^a versus matched controls^b, P value	Antibody-positive 𝑛 (%)		Cases versus benign conditions, P value
Type II malignancies	Cases^a (𝑛=37)	Matched controls^b (𝑛=147)		Cases (𝑛=44)	Benign conditions (𝑛=209)
C. trachomatis IgG	8 (22%)	23 (16%)	.4	8 (18%)	51 (24%)	.4
cHSP60 IgG	10 (27%)	29 (20%)	.4	12 (27%)	48 (24%), 𝑛=202^c	.6
M. genitalium IgG	4 (11%)	5 (3%)	.08	4 (9%)	17 (8%)	.8
Type II with prospective plasma samples^d	Cases^a (𝑛=7)	Matched controls^b (𝑛=28)		Cases (𝑛=7)	Benign conditions with prospective plasma samples (𝑛=22)	Cases versus benign conditions with prospective plasma sample, P value	Cases versus all benign conditions, P value
C. trachomatis IgG	2 (29%)	3 (11%)	.3	2 (29%)	4 (18%)	.6	.7
cHSP60 IgG	6 (86%)	5 (19%), 𝑛=26^c	.002	6 (86%)	6 (30%), 𝑛=20^c	.02	.001
M. genitalium IgG	0	0		0	2 (9%)	1.0	1.0

^aCases with matched controls available.
^bFour controls per case from the NSHDS (Northern Sweden Health and Disease Study) were matched with respect to age and date of plasma-sampling.
^cA few subjects had cHSP60 IgG antibody results that were indeterminant and therefore excluded from the statistical analyses. Assigning them extreme values (all positive or all negative) did not change the main outcomes.
^dA subgroup of type II malignancies where plasma samples were drawn 1.3 to 5.1 years prior to diagnosis.
The Pearson chi-square was used first,and when the expected frequency was <5, Fisher’s exact test was used.